TNGXTango Therapeutics, Inc.
Price
+213%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growing in the filings, the market undecided.
TNG456 is a brain-penetrant PRMT5 inhibitor. In May 2025, the first patient was treated with TNG456 in the dose escalation portion of the Phase 1/2 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and antitumor activity of TNG456 as a monotherapy. The trial is currently enrolling patients with MTAP-deleted solid tumors, with a focus on GBM. We anticipate providing a safety and efficacy update from this trial in 2026.
In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Tango Therapeutics, Inc. (TNGX) reported revenue of $3.7M in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with net loss of $55M. For the full year FY2025, revenue was $62M (+48% year on year) and net income −$102M. Its largest product in Q2 2024 (quarter ended Jun 30, 2024) was License at $12M, 61% of the disclosed total, well ahead of Collaboration at 39%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026As previously disclosed, on November 21, 2025, Tango Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole …Other event · Form 8-K
- Aug 11, 2026Tango Therapeutics Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Aug 6, 2026Dr. Barbara Weber’s employment with Tango Therapeutics, Inc. (the “Company”) as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026 (the “Employment Agreement”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2024 · $19.9MThe company’s own SEC segment disclosure.
- License$12.1M61%
- Collaboration$7.8M39%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.